cord blood-derived hematopoietic progenitor natural killer cell immunotherapy (CHU Sainte-Justine)

N/A

Report date: 2025/03/18 18:23:44

Base Information

Drug Namecord blood-derived hematopoietic progenitor natural killer cell immunotherapy (CHU Sainte-Justine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Umbilical cord stem cell therapy

Mechanisms of ActionNatural killer cells stimulantsImmunostimulants

TargetsUpdating

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesChu De Quebec-Universite Laval

China Registration ClassN/A

Develop Information

Active CompaniesChu De Quebec-Universite Laval

Inactive CompaniesN/A

Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A